Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.84 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059466 | 1.00 | LRRK2 (0.84) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135884 | 0.91 | LRRK2 (1.00) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135882 | 0.91 | LRRK2 (1.00) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135900 | 0.86 | LRRK2 (0.76) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135899 | 0.86 | LRRK2 (0.76) | LRRK2CSF1RPDGFRA | |
| SCHEMBL14059519 | 0.85 | LRRK2 (0.88) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135864 | 0.85 | LRRK2 (0.88) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135930 | 0.84 | LRRK2 (0.73) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135928 | 0.84 | LRRK2 (0.73) | LRRK2CSF1RPDGFRA | |
| SCHEMBL17135861 | 0.84 | LRRK2 (0.76) | LRRK2CSF1RPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | claimed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | claimed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2726465-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | Elan Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2012162254-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | LRRK2 1/4885CSF1R 1563/4885PDGFRA 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.